Sosei Heptares Seeks Acquisitions After $200m Boost

Looking To Add $50-100m In Revenues Per Year

The Japanese firm with R&D operations in the UK is conducting a search to find "a potentially transformative acquisition," helped by a significant financing round.

Chest - money
Sosei Heptares has added to its M&A warchest • Source: Shutterstock

Sosei Heptares has completed an international offering that has raised $200m and is on the lookout for late-stage products or companies to buy.

The Japanese company, which has a strong presence in the UK through its acquisitions of Heptares Therapeutics Ltd. in...

More from Deals

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By 

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By 

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By 

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.

More from Business

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By 

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.